OAB Medications: An Update and What to Use When
Urologists and those practicing urology need a thorough knowledge of the most recent developments and techniques in urology to ensure the highest standards of patient care and safety. This course is designed to inform on the areas that are deemed most essential: Female Pelvic Medicine, Bladder Cancer, Pediatric Urology, Endourology and Urolithiasis, BPH/LUTS, Reconstruction and Trauma, and Testicular Cancer.
At the conclusion of this course, participants will be able to:
Female Pelvic Medicine:
- Describe treatment options for common female urologic conditions.
- Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB).
- Explain the risk-stratified clinical framework for the management of non-metastatic muscle-invasive and non-muscle invasive urothelial bladder cancer.
- Identify treatment options for non-metastatic muscle-invasive bladder cancer including chemotherapy, cystectomy, urinary diversion, lymphadenectomy, and various bladder preserving options.
- Discuss the diagnosis of muscle-invasive bladder cancer and the use of urine markers in addition to variant histologies, resection, intravesical therapy, BCG therapy, cystectomy, enhanced cystoscopy and patient follow-up.
- Integrate AUA guidelines into clinical practice.
- Diagnose, manage and provide consultation for complications such as hydronephrosis and bladder exstrophy.
- Diagnose and provide cost-effective management of common pediatric urology problems including Ureterocele and Ectopic Ureter.
- Outline evaluation, medical and surgical management, of common postnatal obstruction of the urinary tract, including UPJ obstruction, UVJ obstruction and posterior urethral valves.
Endourology and Urolithiasis:
- Interpret metabolic evaluations for patients with kidney stones according to the published guidelines.
- Discuss the use of medications in the prevention of kidney stones, including side effects.
- Outline dietary considerations used for the prevention of stones.
- Explain the recommended preoperative evaluation for patients considering kidney stone surgery (including laboratory studies and imaging).
- Describe a surgical treatment plan for patients with kidney and/or ureteral stones in adult and pediatric patients, including surgical approach and discussion of complications.
- Explain the role of diagnostic testing in making the accurate diagnosis of male LUTS using the new BPH Guidelines.
- Identify common pathophysiological etiologies of voiding and sexual health.
- Define the safety and efficacy of new minimally invasive options for BPH including prostatic urethral lift and convective water vapor therapy and surgical options such as Aquablation and electrosurgical and laser therapies.
- Describe the impact of current therapeutic strategies on both voiding and sexual dysfunction.
- Differentiate among the variety of etiologies of ureteral strictures.
- Describe and summarize radio-graphic testing to accurately define the stricture.
- Identify key steps in surgical techniques to provide for best possible surgical results.
- Describe guidelines-driven, evidence-based treatment algorithms for injuries to the kidney, ureter, bladder, urethra and external genitalia.
- Distinguish between injuries that require non-operative surveillance, immediate surgery, and adjunctive interventions such as angio-embolization or endourologic management.
- Describe treatment options for patients with clinical stages I, IIA, and IIB seminoma and nonseminomatous (NSGCT) germ cell tumors and utilize the low-stage testis cancer treatment algorithm.
Thursday, 21 November 2019
13:00 - 13:35 SUA Welcome Remarks – Raed A. Azhar, MD, SUA President
AUA Welcome Remarks – Sam S. Chang, MD, MBA, AUA Assistant Secretary
Oncology: Bladder Cancer
13:00 – 13:20 Urinary Markers and Cytology: Review and Update (Chang)
13:20 - 13:40 Management of NMIBC: Practical solutions for Common Problems (Chang)
13:40 – 14:00 Bladder Sparing Regimens: Do They Work? (Chang)
14:00 – 14:20 Optimizing Peri-operative Care for Cystectomy Patients (Chang)
14:20 – 15:10 Tumor Board: Case Presentations
15:10 – 15:20 AUA 2019 Take Home Messages – Bladder Cancer (Chang)
15:20 - 15:35 Urinary Tract Reconstruction in Children (Donohoe)
15:35 – 15:50 Ureterocele and Ectopic Ureter (Donohoe)
15:50 – 16:05 Bladder Exstrophy (Donohoe)
16:05 – 16:20 Posterior Urethral Valves (Donohoe)
16:20 – 16:50 Pediatric Urology Case Presentations
16:50 – 17:00 AUA 2019 Take Home Messages – Pediatric Urology (Donohoe)
Friday, 22 November 2019
08:00 – 09:00 Resident Breakfast with the Expert – Female Urology and/or Pediatrics?
Female Pelvic Medicine
09:00 – 09:20 UDS: Unique and key findings (Gomelsky)
09:20 – 09:40 Interstitial Cystitis: Update (Gomelsky)
09:40 – 10:10 Female Pelvic Medicine Case Presentations
10:10 – 10:30 Treatment of Vesico-vaginal Fistula (Gomelsky)
10:30 – 10:50 Treatment of Incontinence and Prolapse (Gomelsky)
11:10 – 11:30 OAB Medications: An Update and What to Use When (Gomelsky)
11:30 – 11:40 AUA 2019 Take Home Messages – Female Pelvic Medicine (Gomelsky)
11:40 – 13:30 Afternoon Break
Endourology and Urolithiasis
13:30 – 13:50 Surgical Treatment of Urolithiasis: State of the Art and What’s New? (Cheney)
13:50 – 14:10 Endourology Complications: How to Avoid Them and How to Manage Them? (Cheney)
14:10 – 14:30 Stone Prevention: Where Are We Now and Where Do We Need to Go? to go? (Cheney)
14:30 – 14:45 Comparing Outcomes of ESWL vs. Ureteroscopy (Cheney)
14:45 – 15:15 Afternoon Coffee Break
15:15 – 16:00 Surgical Techniques: Tips & Tricks: Percutaneous Nephrolithotomy/Urteroscopy (PCNL/URS) – Video Panel
16:00 – 16:50 Endourology and Urolithiasis Case Presentations
16:50 – 17:00 AUA 2019 Take Home Messages – Urolithiasis and Endourology (Cheney)
Saturday, 23 November 2019
08:00 – 09:00 Resident Breakfast with the Expert – Chang and Sexton?
09:00 – 09:20 Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline (Cheney)
09:20 – 09:40 Comparison of Surgical Treatment Options for BPH (Cheney)
09:40 – 10:10 Didactic Lecture or Video Session - Minimally Invasive Techniques for Treating BPH/LUTS (Urolift, Rezum, HoLEP, etc.)
10:10 – 10:20 AUA 2019 Take Home Messages – BPH/LUTS (Cheney)
10:20 – 10:35 Treatment of urethral stricture disease- Guidelines and What is Important (McCammon)
10:35 – 10:50 Urologic Trauma: Evaluation and Treatment—Upper tract (McCammon)
11:50 – 11:05 Urologic Trauma: Evaluation and Treatment—Lower Tract (McCammon)
11:05 – 11:20 Peyronie’s Disease: New Management Strategies (McCammon)
11:20 – 11:40 Adolescence medicine or Transitional medicine (McCammon)
11:40 – 13:00 Afternoon Break
13:00 – 13:30 Urologic Reconstruction and Trauma Case Presentations
13:30 – 13:40 AUA 2019 Take Home Messages – Urologic Reconstruction & Trauma (McCammon)
13:40 – 14:00 AUA Guideline: Diagnosis and Treatment of Early Stage Testicular Cancer (Sexton)
14:00 – 14:20 Treatment for Late Relapse and Salvage Therapies (Sexton)
14:20 – 14:45 Screening and Epidemiology Changes: Is Testis Cancer Becoming More Common? (Sexton)
14:45 – 15:15 Afternoon Coffee Break
15:15 – 15:35 Upper Tract Urothelial Carcinoma: Neoadjuvant or Adjuvant Chemotherapy (Sexton)
15:35 – 15:55 Robotic Surgery for Upper Tract Cancer (Sexton)
15:55 – 16:20 Video or Case Presentation Session: Robotic Surgery or Upper Tract Cancer Treatments
16:20 – 16:30 Penile, Testis, and Urethral Cancer Take Home Message (Sexton)
16:30 – 16:50 Targeted Therapy and Gene Sequencing (?Saudi faculty?)
16:50 – 17:00 What Can AUA Do For You and AUA/SUA Collaborations (Chang/Azhar)
17:00 Closing Remarks/Adjourn - Raed A. Azhar, MD, SUA President
Faculty disclosures will be posted here prior to the start of the course.
Education Council Disclosures
AUA Office of Education Staff have nothing to disclose.
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this live activity for a maximum of 15.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 15.75 AMA PRA Category 1 Credit™
- 15.75 Non-Physician Participation
AUA Participant Information and Policies
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.
Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.